EverSource Wealth Advisors LLC Acquires 85 Shares of Danaher Co. (NYSE:DHR)

EverSource Wealth Advisors LLC grew its holdings in Danaher Co. (NYSE:DHR) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,297 shares of the conglomerate’s stock after purchasing an additional 85 shares during the period. EverSource Wealth Advisors LLC’s holdings in Danaher were worth $300,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Danaher during the 4th quarter valued at $1,752,382,000. Wellington Management Group LLP lifted its holdings in shares of Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Allen Investment Management LLC increased its holdings in Danaher by 1,440.7% during the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after acquiring an additional 1,028,976 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Danaher in the 3rd quarter worth approximately $178,850,000. Finally, Alecta Tjanstepension Omsesidigt purchased a new position in shares of Danaher during the 4th quarter valued at $161,994,000. Institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The disclosure for this sale can be found here. In the last quarter, insiders sold 172,540 shares of company stock valued at $43,523,481. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.2 %

Shares of DHR traded up $0.64 on Friday, hitting $262.04. 500,971 shares of the stock traded hands, compared to its average volume of 2,676,604. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. Danaher Co. has a one year low of $182.09 and a one year high of $268.98. The company has a market capitalization of $194.09 billion, a PE ratio of 44.31, a P/E/G ratio of 4.09 and a beta of 0.83. The business has a 50 day simple moving average of $249.70 and a 200 day simple moving average of $238.20.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the previous year, the firm earned $2.36 EPS. Danaher’s revenue was down 2.6% on a year-over-year basis. As a group, equities analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.41%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Ratings Changes

Several research firms recently commented on DHR. Raymond James boosted their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. TD Cowen upped their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. KeyCorp lifted their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Finally, Royal Bank of Canada boosted their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.